The Prognostic Value of JUNB-positive CTCs in Metastatic Breast Cancer: from Bioinformatics to Phenotypic Characterization

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2019 Aug 3

PMID 31370904

Citations 16

Authors

Galatea Kallergi

Vasileia Tsintari

Stelios Sfakianakis

Ekaterini Bei

Eleni Lagoudaki

Anastasios Koutsopoulos

Nefeli Zacharopoulou

Saad Alkahtani

Saud Alarifi

Christos Stournaras

Michalis Zervakis

Vassilis Georgoulias

Affiliations

Soon will be listed here.

Abstract

Background: Circulating tumor cells (CTCs) are important for metastatic dissemination of cancer. They can provide useful information, regarding biological features and tumor heterogeneity; however, their detection and characterization are difficult due to their limited number in the bloodstream and their mesenchymal characteristics. Therefore, new biomarkers are needed to address these questions.

Methods: Bioinformatics functional enrichment analysis revealed a subgroup of 24 genes, potentially overexpressed in CTCs. Among these genes, the chemokine receptor CXCR4 plays a central role. After prioritization according to the CXCR4 corresponding pathways, five molecules (JUNB, YWHAB, TYROBP, NFYA, and PRDX1) were selected for further analysis in biological samples. The SKBR3, MDA-MB231, and MCF7 cell lines, as well as PBMCs from normal (n = 10) blood donors, were used as controls to define the expression pattern of all the examined molecules. Consequently, 100 previously untreated metastatic breast cancer (mBC) patients (n = 100) were analyzed using the following combinations of antibodies: CK (cytokeratin)/CXCR4/JUNB, CK/NFYA/ΥWHΑΒ (14-3-3), and CK/TYROBP/PRDX1. A threshold value for every molecule was considered the mean expression in normal PBMCs.

Results: Quantification of CXCR4 revealed overexpression of the receptor in SKBR3 and in CTCs, following the subsequent scale (SKBR3>CTCs>Hela>MCF7>MDA-MB231). JUNB was also overexpressed in CTCs (SKBR3>CTCs>MCF7>MDA-MB231>Hela). According to the defined threshold for each molecule, CXCR4-positive CTCs were identified in 90% of the patients with detectable tumor cells in their blood. In addition, 65%, 75%, 14.3%, and 12.5% of the patients harbored JUNB-, TYROBP-, NFYA-, and PRDX-positive CTCs, respectively. Conversely, none of the patients revealed YWHAB-positive CTCs. Interestingly, JUNB expression in CTCs was phenotypically and statistically enhanced compared to patients' blood cells (p = 0.002) providing a possible new biomarker for CTCs. Furthermore, the detection of JUNB-positive CTCs in patients was associated with poorer PFS (p = 0.015) and OS (p = 0.002). Moreover, JUNB staining of 11 primary and 4 metastatic tumors from the same cohort of patients revealed a dramatic increase of JUNB expression in metastasis.

Conclusions: CXCR4, JUNB, and TYROBP were overexpressed in CTCs, but only the expression of JUNB was associated with poor prognosis, providing a new biomarker and a potential therapeutic target for the elimination of CTCs.

Citing Articles

STIM1, ORAI1, and KDM2B in circulating tumor cells (CTCs) isolated from prostate cancer patients.

Roumeliotou A, Alkahtani S, Alarifi S, Alkahtane A, Stournaras C, Kallergi G Front Cell Dev Biol. 2024; 12:1399092.

PMID: 38903530 PMC: 11188415. DOI: 10.3389/fcell.2024.1399092.

Genome-wide CRISPR/Cas9 screen reveals JunB downmodulation of HIV co-receptor CXCR4.

Schulze W, Gregory D, Johnson M, Lange M Front Microbiol. 2024; 15:1342444.

PMID: 38835488 PMC: 11149427. DOI: 10.3389/fmicb.2024.1342444.

Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients.

Roumeliotou A, Strati A, Chamchougia F, Xagara A, Tserpeli V, Smilkou S Cells. 2024; 13(9.

PMID: 38727318 PMC: 11083423. DOI: 10.3390/cells13090782.

Liquid biopsy biomarkers to guide immunotherapy in breast cancer.

Yang J, Qiu L, Wang X, Chen X, Cao P, Yang Z Front Immunol. 2023; 14:1303491.

PMID: 38077355 PMC: 10701691. DOI: 10.3389/fimmu.2023.1303491.

Comprehensive Analysis of Purine-Metabolism-Related Gene Signature for Predicting Ovarian Cancer Prognosis, Immune Landscape, and Potential Treatment Options.

Liu J, Zhang X, Wang H, Zuo X, Hong L J Pers Med. 2023; 13(5).

PMID: 37240946 PMC: 10219580. DOI: 10.3390/jpm13050776.

References

Papadaki M, Kallergi G, Zafeiriou Z, Manouras L, Theodoropoulos P, Mavroudis D . Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. BMC Cancer. 2014; 14:651. PMC: 4161777. DOI: 10.1186/1471-2407-14-651. View

Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, Apostolaki S . Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol. 2002; 20(16):3404-12. DOI: 10.1200/JCO.2002.08.135. View

Sfakianakis S, Bei E, Zervakis M, Vassou D, Kafetzopoulos D . On the identification of circulating tumor cells in breast cancer. IEEE J Biomed Health Inform. 2014; 18(3):773-82. DOI: 10.1109/JBHI.2013.2295262. View

Sundqvist A, Morikawa M, Ren J, Vasilaki E, Kawasaki N, Kobayashi M . JUNB governs a feed-forward network of TGFβ signaling that aggravates breast cancer invasion. Nucleic Acids Res. 2017; 46(3):1180-1195. PMC: 5814809. DOI: 10.1093/nar/gkx1190. View

Pei H, Guo Z, Wang Z, Dai Y, Zheng L, Zhu L . RAC2 promotes abnormal proliferation of quiescent cells by enhanced JUNB expression via the MAL-SRF pathway. Cell Cycle. 2018; 17(9):1115-1123. PMC: 6110603. DOI: 10.1080/15384101.2018.1480217. View

Ignatiadis M, Rothe F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C . HER2-positive circulating tumor cells in breast cancer. PLoS One. 2011; 6(1):e15624. PMC: 3018524. DOI: 10.1371/journal.pone.0015624. View

Muller A, Homey B, Soto H, Ge N, CATRON D, Buchanan M . Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410(6824):50-6. DOI: 10.1038/35065016. View

Lobodasch K, Frohlich F, Rengsberger M, Schubert R, Dengler R, Pachmann U . Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: an increase in cell number at completion of therapy is a predictor of early relapse. Breast. 2007; 16(2):211-8. DOI: 10.1016/j.breast.2006.12.005. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

10.

Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A . Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol. 2006; 24(23):3756-62. DOI: 10.1200/JCO.2005.04.5948. View

11.

Kallergi G, Papadaki M, Politaki E, Mavroudis D, Georgoulias V, Agelaki S . Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011; 13(3):R59. PMC: 3218948. DOI: 10.1186/bcr2896. View

12.

Lian S, Shao Y, Liu H, He J, Lu W, Zhang Y . PDK1 induces JunB, EMT, cell migration and invasion in human gallbladder cancer. Oncotarget. 2015; 6(30):29076-86. PMC: 4745712. DOI: 10.18632/oncotarget.4931. View

13.

Edgar R, Domrachev M, Lash A . Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2001; 30(1):207-10. PMC: 99122. DOI: 10.1093/nar/30.1.207. View

14.

Kallergi G, Agelaki S, Papadaki M, Nasias D, Matikas A, Mavroudis D . Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. Breast Cancer Res. 2015; 17:113. PMC: 4541732. DOI: 10.1186/s13058-015-0624-x. View

15.

Messaritakis I, Politaki E, Kotsakis A, Dermitzaki E, Koinis F, Lagoudaki E . Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer. PLoS One. 2017; 12(7):e0181211. PMC: 5515424. DOI: 10.1371/journal.pone.0181211. View

16.

Gokulnath M, Swetha R, Thejaswini G, Shilpa P, Selvamurugan N . Transforming growth factor-β1 regulation of ATF-3, c-Jun and JunB proteins for activation of matrix metalloproteinase-13 gene in human breast cancer cells. Int J Biol Macromol. 2016; 94(Pt A):370-377. DOI: 10.1016/j.ijbiomac.2016.10.026. View

17.

Staber P, Vesely P, Haq N, Ott R, Funato K, Bambach I . The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood. 2007; 110(9):3374-83. DOI: 10.1182/blood-2007-02-071258. View

18.

Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G . Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol. 2012; 23(7):1744-50. DOI: 10.1093/annonc/mds020. View

19.

Nagrath S, Sequist L, Maheswaran S, Bell D, Irimia D, Ulkus L . Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007; 450(7173):1235-9. PMC: 3090667. DOI: 10.1038/nature06385. View

20.

Hicks M, Hu Q, Macrae E, DeWille J . JUNB promotes the survival of Flavopiridol treated human breast cancer cells. Biochem Biophys Res Commun. 2014; 450(1):19-24. DOI: 10.1016/j.bbrc.2014.05.057. View